Yuichi Muraki

Prof. Dr. Yuichi Muraki

Kyoto Pharmaceutical University
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Closed access
YMYuichi Muraki
Yuichi Muraki
TYTetsuya Yagi
Tetsuya Yagi
YTYasuhiro Tsuji
Yasuhiro Tsuji
NNNobuhiro Nishimura
Nobuhiro Nishimura
MTMasaki Tanabe
Masaki Tanabe
MOMasahiro Okuda
Masahiro Okuda

1 February 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Open access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
YNYoshihito Niki
Yoshihito Niki

1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
YKYoshiki Kusama
Yoshiki Kusama
STShinya Tsuzuki
Shinya Tsuzuki
YMYuichi Muraki
Yuichi Muraki
RKRyuji Koizumi
Ryuji Koizumi
MIMasahiro Ishikane
Masahiro Ishikane
NONorio Ohmagari
Norio Ohmagari
The aim of this study was to estimate the effects of Japan's National Action Plan on Antimicrobial Resistance 2016-2020 (NAP) on antimicrobial use (AMU). Monthly AMU from January 2013 to December 2019 was calculated using sales data, and time-series charts of AMU were then created for the total antimicrobials and target drug categories shown in the NAP (oral cephalosporins, oral fluoroquinolones, oral macrolides, and parenteral antimicrobials). Twelve-month predictions were generated to evaluate AMU in 2020. The publication of the NAP was associated with an AMU reduction in total antimicrobials, cephalosporins, fluoroquinolones, and macrolides. Parenteral AMU showed an upward trend, although it was not significantly associated with the intervention effect. AMU reductions of 15.0% for total antimicrobials, 26.3% for cephalosporins, 23.5% for fluoroquinolones, and 24.6% for macrolides were predicted for 2020 relative to 2013. However, there was a predicted increase of 17.4% for parenteral AMU. While Japan's NAP has contributed to the reduction in national AMU over the past 5 years, sustained action is still needed to further improve antimicrobial stewardship and promote countermeasures to antimicrobial resistance.

1 September 2019 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
TKTatsuya Kawaguchi
Tatsuya Kawaguchi

1 January 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
MMMasayuki Maeda
Masayuki Maeda
YMYuichi Muraki
Yuichi Muraki
TKTadashi Kosaka
Tadashi Kosaka
TYTakehiro Yamada
Takehiro Yamada
YAYosuke Aoki
Yosuke Aoki
TKTatsuya Kawaguchi
Tatsuya Kawaguchi

28 December 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AOAkane Ono
Akane Ono
MIMasahiro Ishikane
Masahiro Ishikane
YKYoshiki Kusama
Yoshiki Kusama
CTChika Tanaka
Chika Tanaka
SOSachiko Ono
Sachiko Ono
NONorio Ohmagari
Norio Ohmagari
Purpose: To counter the global health threat of antimicrobial resistance, effective antimicrobial stewardship programs are needed to improve antimicrobial use (AMU) among dentists in addition to physicians. This study aimed to investigate the nationwide epidemiology of AMU among Japanese dentists to facilitate the development of dentist-centered programs. Methods: We conducted a retrospective population-based study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan to analyze the AMU among Japanese dentists between 2015 and 2017. AMU was quantified as the defined daily doses per 1,000 inhabitants per day (DID). The trends in dentist-prescribed AMU were examined according to antimicrobial category and administration route. We also compared outpatient oral AMU between dentists and physicians as well as between on-site and off-site dispensing. Results: The DID values of dentist-prescribed AMU were 1.23 in 2015, 1.22 in 2016, and 1.21 in 2017. During this study period, outpatient oral antimicrobials comprised the majority (approximately 99%) of dentist-prescribed AMU, and cephalosporins were the most frequently prescribed antimicrobials (>60% of all antimicrobials). The DID values of outpatient oral AMU were 1.21 for dentists and 12.11 for physicians. The DID value for on-site dispensing was 0.89 in 2017, in which cephalosporins were the predominantly used antimicrobials (DID: 0.60). Conclusions: Interventions that target dentists in Japan should focus on on-site dispensing of oral antimicrobials (especially cephalosporins) for outpatients. Further studies are needed to ascertain the underlying factors of oral cephalosporin prescriptions to guide the development of effective antimicrobial stewardship programs.